Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
Executive Summary
Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.
You may also be interested in...
Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline
Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.
Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline
Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.
US Retail Drug Spending Growth Slows Substantially In 2016
Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.